Pharmaceuticals & Therapeutics

A new natural suppository aims to break the cycle of recurrent yeast infections by supporting the vaginal microbiome, offering hope to millions of women.

Florida's Dunamis Premium Spirits is making waves, targeting the global cruise market with its award-winning, mission-driven brands. Here's how.

With Nuvaxovid set for a 2026 rollout, Sanofi aims to address vaccine hesitancy and expand choices as Canada continues to battle the virus.

With a personal family connection to type 1 diabetes and a £100M war chest, Anastasia Bukhman joins the T1D Fund's board to speed up research.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

1 Hotel Hanalei Bay blends cutting-edge biohacking with the raw power of nature, aiming to redefine luxury wellness. Is this the future of health travel?

With its European trial launch, Kainova's DT-7012 aims to disarm cancer's bodyguards, offering new hope for patients with advanced solid tumors.

Treating over 100,000 patients in two years, a novel gel therapy is leading a paradigm shift in interventional dry eye management. Here's how.

Eli Lilly's new once-daily oral GLP-1, Foundayo, is now on telehealth platform Ro, offering a convenient, needle-free alternative to injectable drugs.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

Absci will showcase its generative AI drug discovery platform at a key healthcare conference, highlighting its ambitious pipeline for hair loss and endometriosis.

With its future riding on a pivotal trial for avexitide, Amylyx's upcoming conference presentation offers a crucial look into its post-ALS strategy.

Altruist Biologics secures a landmark license for China's largest bioreactor facility, signaling a major shift in the global biopharmaceutical supply chain.

With a $137M war chest, Sidewinder Therapeutics is advancing a new class of ultra-precise cancer drugs aimed at tumors that have long evaded treatment.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

The dermatologist-founded brand is expanding access to clinical-grade treatments for underserved skin concerns, signaling a major shift in the industry.

Hemispherian launches a landmark trial for GLIX1, a first-in-class therapy aiming to selectively destroy glioblastoma cells where others have failed.

A new alliance between Daiichi Sankyo and ATLATL aims to leverage a unique 'Super Server' model to fast-track novel therapies from Asia to the world.

Lupin wins FDA approval for its generic dapagliflozin, a move set to slash costs for a blockbuster diabetes and heart drug and reshape patient care.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?